Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year (ERASURE)

INTERVENTION: Intervention name : AIN457 INN of the intervention : Secukinumab Dosage And administration of the intervention : Subcutaneous Injection CONDITION: psoriasis PRIMARY OUTCOME: Efficacy of secukinumab in subjects with moderate to severe chronic plaque‐type psoriasis [ Time Frame: 12 weeks ] SECONDARY OUTCOME: Efficacy of secukinumab in subjects with moderate to severe chronic plaque‐type psoriasis [ Time Frame: 52 weeks ] INCLUSION CRITERIA: ‐Moderate and severe plaque‐type psoriasis diagnosed for at least 6 months.